Advantages of Sirolimus in a Calcineurin-Inhibitor Minimization Protocol for the Immunosuppressive Management of Kidney Allograft Recipients

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td align="left">Immunosuppressive regimen*</td><td align="center">Total cases</td><td align="center">Rejection or graft loss cases</td><td align="center">Percent rejection or graft loss</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td align="left">MMF/Pred/Cyclo</td><td align="center">74</td><td align="center">10</td><td align="center">13.5%</td></tr><tr><td align="left">MMF/Pred/Tacro</td><td align="center">11</td><td align="center">3</td><td align="center">27.3%</td></tr><tr><td align="left">MMF/Pred/Cyclo/Siro</td><td align="center">20</td><td align="center">1</td><td align="center">5.0%</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><b>
                  *
                </b>MMF: mycophenolate mofetil, PRED: prednisone, CYCLO: cyclosporin A, TACRO: tacrolimus,    SIRO: sirolimus.<br/></td></tr></table>

Effect of immunosuppressive regimen on graft rejection or loss.

International Scholarly Research Notices

tab2

Table 2

Table 2: Advantages of Sirolimus in a Calcineurin-Inhibitor Minimization Protocol for the Immunosuppressive Management of Kidney Allograft Recipients 

Table 2 | Advantages of Sirolimus in a Calcineurin-Inhibitor Minimization Protocol for the Immunosuppressive Management of Kidney Allograft Recipients 